Gland Pharma Limited, a generic injectable-focused pharmaceutical company, has achieved a milestone with the approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial.

This approval marks a key moment for Gland Pharma as the product is anticipated to be the first generic approval on the market. The company plans to launch the product in the near term through its marketing partner, leveraging its expertise in the pharmaceutical industry.

The product, with US sales reaching approximately USD 92 million for the twelve months ending in February 2024, according to IQVIA, presents a substantial opportunity for Gland Pharma to penetrate the market and meet the demand for affordable pharmaceutical solutions.

In a strategic collaboration, Gland Pharma is co-developing several complex injectables, including the newly approved product, with Orbicular Pharmaceutical Technologies Private Limited.